Back to top

Press Releases

Zacks Equity Research

The Zacks Analyst Blog Highlights: Teva Pharmaceutical Industries, Intel, Sanofi, Alphabet and Qualcomm


Trades from $3

For Immediate Release

Chicago, IL – September 27, 2016 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Teva Pharmaceutical Industries Ltd. (NYSE: (TEVA - Analyst Report) -Free Report ), Intel Corporation (NASDAQ: (INTC - Analyst Report) -Free Report ), Sanofi (NYSE: (SNY - Analyst Report) -Free Report ), Alphabet (NASDAQ: (GOOGL - Analyst Report) -Free Report ) and Qualcomm Incorporated (NASDAQ: (QCOM - Analyst Report) -Free Report ).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday’s Analyst Blog:

The Internet of Medical Things: 5 Stocks in Focus

The Internet of Medical Things (IoMT) is fast gaining pace as pharma companies look to innovate and keep up with technology to help patients and physicians better monitor and track diseases. With a couple of deals being announced this month, IoMT seems like the future of healthcare.

IoMT – A Healthcare Revolution

IoMT involves the bringing together of technology and medical devices and applications. Chronic diseases which require frequent monitoring can be tracked effectively so that patients receive timely and proper treatment. It is already a part of our daily lives in the form of wearable devices like Apple Watch, Fitbit and Samsung S Health which help users achieve their fitness and health targets.

Pharma and tech companies are now taking things a step further and are collaborating to make devices that can track chronic and lifestyle associated diseases like diabetes which are growing at a fast pace.

In fact, the scope for innovation in this area is endless -- contact lenses that can detect glucose levels, a device that can monitor caloric intake, bioelectronic medicines that can tackle and maybe treat a wide range of chronic diseases, robotic-assisted surgery – all these are actually some of the widely interesting areas covered by IoMT.

As more deals between pharma and tech companies get announced, it makes sense to take a look at some of the key players in this rapidly evolving area.

Teva Pharmaceutical Industries Ltd. (NYSE: (TEVA - Analyst Report) -Free Report ) signed up with Intel Corporation (NASDAQ: (INTC - Analyst Report) -Free Report ) in mid-September to develop a wearable device and machine learning platform that can be used in Huntington disease (HD). Patients in an ongoing study will use a smartphone and wear a smartwatch equipped with sensing technology which will continuously monitor their general functioning and movement. The data will be wirelessly streamed to a cloud-based platform specifically developed by Intel to analyze data from wearable devices. The data will then be translated in near real-time into objective scores of motor symptom severity which in turn will help improve understanding regarding disease progression and the impact of treatment. Intel is a Zacks Rank #2 (Buy) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here .

Another pharma-tech deal that made news this month is the joint venture (JV) between French drugmaker, Sanofi (NYSE: (SNY - Analyst Report) -Free Report ), and Verily Life Sciences, an Alphabet (NASDAQ: (GOOGL - Analyst Report) -Free Report ) company. The JV, Onduo, will be focused on the development of comprehensive solutions that combine devices, software, medicine, and professional care to enable simple and intelligent disease management for diabetics. Sanofi’s expertise in diabetes will be combined with Verily’s experience in miniaturized electronics, analytics, and consumer software development.

Qualcomm Incorporated (NASDAQ: (QCOM - Analyst Report) -Free Report ) is another company that is quite active in the area of healthcare Internet of Things (IoT). Through its subsidiary Qualcomm Life, Inc., Qualcomm recently signed a deal with Boehringer Ingelheim that will see the companies collaborating to improve chronic obstructive pulmonary disease (COPD) care. The deal covers the development of a connectivity solution for Boehringer's Respimat inhaler to help improve COPD treatment outcomes.

In Conclusion

With technology touching most aspects of our lives, it won’t be surprising to see more such collaborations going forward. According to a report issued by P&S Market Research earlier this year, the global IoT in Healthcare market was valued at approximately $24.7 billion in 2014, and is expected to grow 37.6% (CAGR) during 2015 - 2020.

Where Do Zacks' Investment Ideas Come From?

You are welcome to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buy" stocks free of charge. There is no better place to start your own stock search. Plus you can access the full list of must-avoid Zacks Rank #5 "Strong Sells" and other private research. See the stocks free >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on TEVA - FREE

Get the full Report on INTC - FREE

Get the full Report on SNY - FREE

Get the full Report on GOOGL - FREE

Get the full Report on QCOM - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.